bluebird bio (BLUE) News Today $4.08 -2.96 (-42.05%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$4.00 -0.08 (-1.96%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Bluebird Bio to Be Acquired by Carlyle Group, SK CapitalFebruary 21 at 11:03 PM | msn.comBluebird Bio trading halted, volatility trading pauseFebruary 21 at 6:01 PM | markets.businessinsider.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.February 21 at 3:43 PM | prnewswire.comOnce high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy makerFebruary 21 at 2:02 PM | cnbc.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of bluebird bio, Inc. - BLUEFebruary 21 at 12:30 PM | prnewswire.comShareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public ShareholdersFebruary 21 at 9:02 AM | businesswire.comBLUE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of bluebird bio, Inc. Is Fair to ShareholdersFebruary 21 at 8:52 AM | businesswire.combluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK CapitalFebruary 21 at 7:30 AM | businesswire.comHigh-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment modelsFebruary 18, 2025 | cnbc.combluebird bio (NASDAQ:BLUE) Stock Price Passes Below 200-Day Moving Average - Here's What HappenedFebruary 14, 2025 | americanbankingnews.combluebird bio (NASDAQ:BLUE) Stock Price Passes Below Two Hundred Day Moving Average - Should You Sell?bluebird bio (NASDAQ:BLUE) Stock Passes Below 200-Day Moving Average - Here's What HappenedFebruary 14, 2025 | marketbeat.combluebird bio, Inc. (NASDAQ:BLUE) Given Consensus Rating of "Hold" by BrokeragesShares of bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) have been assigned an average rating of "Hold" from the nine analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and two have giFebruary 6, 2025 | marketbeat.comBluebird bio chief business officer Joseph Vittiglio sells $1,759 in stockFebruary 5, 2025 | msn.comBluebird bio's chief commercial officer Klima sells $901 in stockFebruary 5, 2025 | msn.comShort Interest in bluebird bio, Inc. (NASDAQ:BLUE) Drops By 6.6%bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) was the recipient of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 2,410,000 shares, a drop of 6.6% from the December 31st total of 2,580,000 shares. Currently, 25.0% of the shares of the company are sold short. Based on an average daily volume of 405,100 shares, the short-interest ratio is presently 5.9 days.February 3, 2025 | marketbeat.combluebird bio (NASDAQ:BLUE) Share Price Passes Below 200 Day Moving Average - Here's What Happenedbluebird bio (NASDAQ:BLUE) Stock Passes Below 200-Day Moving Average - Time to Sell?February 1, 2025 | marketbeat.comQ4 EPS Estimates for bluebird bio Increased by Analystbluebird bio, Inc. (NASDAQ:BLUE - Free Report) - Research analysts at Leerink Partnrs increased their Q4 2024 EPS estimates for shares of bluebird bio in a research note issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will post earJanuary 24, 2025 | marketbeat.comCantor Fitzgerald Weighs in on bluebird bio FY2025 Earningsbluebird bio, Inc. (NASDAQ:BLUE - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for bluebird bio in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the biotechnology company will earn ($23January 23, 2025 | marketbeat.comCantor Fitzgerald Forecasts bluebird bio FY2025 Earningsbluebird bio, Inc. (NASDAQ:BLUE - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of bluebird bio in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the biotechnology compaJanuary 22, 2025 | marketbeat.combluebird bio, Inc. (NASDAQ:BLUE) Short Interest Updatebluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) was the recipient of a large decrease in short interest in December. As of December 31st, there was short interest totalling 2,410,000 shares, a decrease of 6.6% from the December 15th total of 2,580,000 shares. Currently, 25.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 405,100 shares, the short-interest ratio is presently 5.9 days.January 18, 2025 | marketbeat.com'Will it really work?': Young sickle cell patient among the first to start new gene therapyJanuary 18, 2025 | msn.combluebird bio, Inc. (NASDAQ:BLUE) Given Consensus Rating of "Hold" by AnalystsShares of bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) have been assigned a consensus rating of "Hold" from the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recomJanuary 12, 2025 | marketbeat.comNational Resilience to lay off 120 in North CarolinaJanuary 9, 2025 | finance.yahoo.combluebird bio (NASDAQ:BLUE) Stock Price Passes Below 200-Day Moving Average - Here's Whybluebird bio (NASDAQ:BLUE) Stock Passes Below 200-Day Moving Average - Here's What HappenedJanuary 8, 2025 | marketbeat.comBiotech manufacturer plans to cut 120 jobs in DurhamJanuary 7, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Cencora (COR) and Bluebird Bio (BLUE)January 7, 2025 | markets.businessinsider.comBluebird Bio price target lowered to $8 at RBC Capital on ‘limited cash runway’January 7, 2025 | markets.businessinsider.comBluebird Bio price target adjusted for stock split at BarclaysDecember 31, 2024 | markets.businessinsider.combluebird bio (NASDAQ:BLUE) Price Target Raised to $40.00 at BarclaysBarclays increased their price target on shares of bluebird bio from $2.00 to $40.00 and gave the company an "overweight" rating in a research note on Tuesday.December 31, 2024 | marketbeat.comBluebird Bio’s Strategic Restructuring and Valuation Uplift Justifies Buy RatingDecember 31, 2024 | markets.businessinsider.comBluebird Bio’s Strategic Restructuring and Valuation Uplift Justifies Buy RatingDecember 31, 2024 | markets.businessinsider.combluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | insidermonkey.combluebird bio, Inc. (NASDAQ:BLUE) Sees Significant Decrease in Short Interestbluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) saw a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 2,580,000 shares, a drop of 94.8% from the November 30th total of 49,570,000 shares. Currently, 26.8% of the company's shares are sold short. Based on an average daily volume of 418,200 shares, the days-to-cover ratio is currently 6.2 days.December 26, 2024 | marketbeat.com2seventy bio: All In On Abecma Multiple Myeloma TreatmentDecember 23, 2024 | seekingalpha.comStockNews.com Initiates Coverage on bluebird bio (NASDAQ:BLUE)StockNews.com started coverage on bluebird bio in a research report on Friday. They issued a "sell" rating on the stock.December 20, 2024 | marketbeat.comMarch Biosciences Elects Peter Olagunju as Chair of Board of DirectorsDecember 19, 2024 | markets.businessinsider.combluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Rating of "Hold" from Brokeragesbluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) has earned a consensus rating of "Hold" from the ten ratings firms that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, six have issued a hold recommendationDecember 18, 2024 | marketbeat.combluebird bio (NASDAQ:BLUE) Shares Up 15.3% - Time to Buy?bluebird bio (NASDAQ:BLUE) Trading Up 15.3% - Should You Buy?December 16, 2024 | marketbeat.combluebird bio (NASDAQ:BLUE) Stock Price Down 13.4% - Time to Sell?bluebird bio (NASDAQ:BLUE) Stock Price Down 13.4% - Should You Sell?December 13, 2024 | marketbeat.combluebird bio (NASDAQ:BLUE) Now Covered by Analysts at StockNews.comStockNews.com began coverage on bluebird bio in a research report on Thursday. They set a "sell" rating for the company.December 12, 2024 | marketbeat.combluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and ExpositionDecember 8, 2024 | businesswire.comBluebird Bio participates in CMMI Cell and Gene Therapy Access ModelDecember 5, 2024 | markets.businessinsider.comMakers of Sickle Cell Disease Gene Therapy to Participate in Payment Model, CMS SaysDecember 5, 2024 | msn.comCMS enters agreement with Vertex, bluebird to improve access to gene therapiesDecember 4, 2024 | msn.combluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access ModelDecember 4, 2024 | businesswire.combluebird bio (NASDAQ:BLUE) Coverage Initiated at StockNews.comStockNews.com began coverage on shares of bluebird bio in a report on Wednesday. They issued a "sell" rating on the stock.December 4, 2024 | marketbeat.comFDA investigating safety risks of bluebird's SkysonaNovember 27, 2024 | msn.comFDA investigating safety risks of bluebird's SkysonaNovember 27, 2024 | msn.comFDA probes blood cancer risk from bluebird's gene therapy, weighs regulatory actionNovember 27, 2024 | msn.comFDA probes blood cancer risk from bluebird's gene therapy, weighs regulatory actionNovember 27, 2024 | msn.com Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address BLUE Media Mentions By Week BLUE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLUE News Sentiment▼0.000.60▲Average Medical News Sentiment BLUE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLUE Articles This Week▼115▲BLUE Articles Average Week Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Korro Bio News Today Neumora Therapeutics News Today Y-mAbs Therapeutics News Today Kodiak Sciences News Today Tevogen Bio News Today Neurogene News Today AC Immune News Today Heron Therapeutics News Today Eledon Pharmaceuticals News Today iTeos Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BLUE) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLUE Stock Alerts